vytorin Resources | BNET
On ZDNet: Favorite open source apps

Resources

13 Resources for

vytorin

  • Subscribe to this listing via:
  • RSS
  • Email

BNET Resources

Is Merck Hanging Schering Out to Dry on Vytorin?
Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
Tags: HEALTHCARE, Schering, Vytorin, ENHANCE Trial, Merck & Co. Inc., Zocor
Discussion threads 2008-07-07
Vytorin Fails to Meet Main Goal of Heart Study
By Bill Berkrot and Ransdell Pierson NEW YORK (Reuters) - The cholesterol fighter Vytorin sold by Merck & Co Inc MRK and Schering-Plough Corp SGP failed to meet the main goal of improving outcomes in a closely-watched heart study, according to data presented...
Tags: Schering-Plough Corp., Merck & Co. Inc., cholesterol, researcher, patient, New York, Thomson Reuters Corp., financial, benefit
News items 2008-07-21
Merck Withholds Forecasts After Cholesterol Study
By Lewis Krauskopf and Ransdell Pierson NEW YORK (Reuters) - Merck & Co Inc MRK cut its sales outlook on two key medicines on Monday and indicated its financial forecasts were in doubt after a mostly negative study of cholesterol treatment Vytorin, sending...
Tags: Financial accounting, Merck & Co. Inc., vaccine, earnings, analyst, cost control, cholesterol, Thomson Reuters Corp., New York, DJIA, sales, U.S., CEO, manufacturing, strategy
News items 2008-07-21
Merck, Schering Delay Earnings For Vytorin Update
NEW YORK (Reuters) - Merck & Co MRK and Schering-Plough SGP said they would delay release of company earnings until after the stock market closes on Monday, in order to update investors on a new important study of their shared Vytorin ...
Tags: Investment, Financial accounting, Merck & Co. Inc., Schering-Plough Corp., cholesterol, drug company, patient, stock market, New York, investor, Thomson Reuters Corp., stock, sales
News items 2008-07-21
Schering-Plough Now in the Feds' Crosshairs
Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
Tags: HEALTHCARE, Schering-Plough Corp., Schering, ENHANCE Trial, Vytorin, Zocor, trial result, Merck & Co. Inc.
Discussion threads 2008-07-10
How Pharma Stacks the Deck with Medical Journals
How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
Tags: HEALTHCARE, Schering, ENHANCE Trial, Vytorin, Zocor, trial result
Discussion threads 2008-06-18
Schering-Plough Now in the Feds' Crosshairs
The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious: Investigation and Inquiries.  Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its ...
Tags: SEC, Merck & Co. Inc., Schering-Plough Corp., Attorney, Vytorin, Sales Strategy, Healthcare, Sales Force Management, Sales, David P. Hamilton
Blog posts 2008-05-07
Is Merck Hanging Schering Out to Dry on Vytorin?
A close reading of the Merck and Schering-Plough first-quarter conference calls suggests that Merck is distancing itself from its joint-venture partner -- who is, in any event, in a much worse position to weather the storm over their cholesterol-fighting pill Vytorin. Vytorin, of course, is a combination...
Tags: Merck & Co. Inc., Schering, Vytorin, Sales Strategy, Investment, Financial Services, Sales, Finance, David P. Hamilton
Blog posts 2008-04-23
Merck, Schering Unable to Stop Digging in Vytorin Mess
As an example of how not to handle a corporate crisis, it's hard to beat the growing scandal over Vytorin. That's the blockbuster anti-cholesterol drug whose clinical-trial data Merck and Schering-Plough sat on for a year or two after it showed that Vytorin was apparently no better than a...
Tags: Merck & Co. Inc., Vytorin, House Committee, Sales Strategy, E-mail, Healthcare, Sales, Online Communications, David P. Hamilton
Blog posts 2008-04-14
Vytorin Update: Big Pharma Strikes Back
The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
Tags: Merck & Co. Inc., Pharmaceutical Company, Trial, Vytorin, Sales Strategy, E-mail, Sales, Online Communications, David P. Hamilton
Blog posts 2008-04-03
Vytorin Update: Big Pharma Strikes Back
The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
Tags: Sales force management, David P. Hamilton, Vytorin Update, John Kastelein, Schering
Blog posts 2008-04-03
Marketing Trumps Science in Vytorin Scandal
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
Tags: Merck & Co. Inc., Drug, Vytorin, Zetia, Schering, E-mail, Marketing Research, Online Communications, Marketing, David P. Hamilton
Blog posts 2008-04-01
Marketing Trumps Science in Vytorin Scandal
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
Tags: David P. Hamilton, marketing, Zetia, Vytorin, Schering, Merck & Co. Inc.
Blog posts 2008-04-01

Additional Resources

Research and Markets: Determine the Impact of the ENHANCE Study on Vytorin and Zetia Use
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/4e90d7/vytorin_wave_two) has announced the addition of the "Vytorin: Wave Two - Impact of ENHANCE Trial" report to their offering. A Survey of One-Hundred Three US-based PCP's and Cardiologists Deliverable: Survey with key findings. Study Description: Topic:...
Articles 2008-06-23
Schiffrin Barroway Topaz & Kessler, LLP Announces Court Ruling Relating to Merck & Co. Inc.'s Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, and the Merck Puerto Rico Employee Savings & Security Plan
RADNOR, Pa., June 19 /PRNewswire/ -- ADVERTISEMENT - The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP: Schiffrin Barroway Topaz & Kessler, LLP is Co-Lead Counsel for the ERISA plaintiffs in the In re Merck & Co. Inc. Securities,...
Articles 2008-06-19
Zacks Analyst Blog Highlights: Merck, Alexza Pharmaceuticals, Eastman Chemical, Stoneridge and Abbott Laboratories
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck (NYSE: MRK), Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA), Eastman Chemical (NYSE:...
Articles 2008-06-16
Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
Lawsuit claims manufacturers misled consumers about the use of Zetia and Vytorin. SEATTLE, June 10 /PRNewswire/ -- Last week the U.S. District Court in New Jersey appointed Hagens Berman, along with four other firms, co-counsel in a case against Schering-Plough and Merck which claims the...
Articles 2008-06-10
DIRECT MARKETING: Update
Harte-Hanks has announced plans to close a New Jersey office, one of its 30 company locations nationwide. Jobs lost in the shuffle represented less than 1% of the company's 7,100 employee base, says Doug Shepard, CFO. Tasks performed at the New Jersey facility have been shifted to other locations. ...
Articles 2008-06-01
PR View
Several factors continue to make a case for the economy of PR. First, the ROI of a PR campaign compared to its advertising counterpart remains unchallenged. Even the most expensive national public relations campaign is small marketing peanuts compared to consumer advertising. PR can deliver both as part of...
Articles 2008-06-01
WALL STREET CHOICE: VYTORIN/ZETIA DAMAGE IS NOT AS BAD AS FEARED
Jami Rubin Morgan Stanley Stock: Schering-Plough Price target $20.00 Share price (as of April 4,2008) $16.12 52-Week Range $33.81-13.83 Significant stock sell-off for both Schering-Plough (-25%) and Merck (-15%) after the American College of Cardiology ACC conference thus far looks drastically disproportionate to the...
Articles 2008-05-01
  • << Previous
  • page 1 of 1
  • Next >>